Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +0.83%48 3-Year ROIIC % is 3.13 as of Mar. 2024. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 794 Medical Devices & Instruments companies, RUA Life Sciences ranks better than 53.27% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
RUA Life Sciences's 3-Year ROIIC % for the quarter that ended in Mar. 2024 was 3.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for RUA Life Sciences's 3-Year ROIIC % or its related term are showing as below:
FRA:AOHA's 3-Year ROIIC % is ranked better than 53.27% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 1.455
vs FRA:AOHA: 3.13
RUA Life Sciences (FRA:AOHA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
RUA Life Sciences 3-Year ROIIC % Related Terms
RUA Life Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, RUA Life Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
RUA Life Sciences (FRA:AOHA) has a 3-Year ROIIC % of 3.13 as of Mar. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #371 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 46.7%.
Is RUA Life Sciences' 3-Year ROIIC % too high?
RUA Life Sciences' current 3-Year ROIIC % is 3.13. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.46. RUA Life Sciences' value of 3.13 is 115.1% above this industry median. Based on the distribution chart, RUA Life Sciences ranks #371 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #371 out of 794 companies for 3-Year ROIIC %. This puts RUA Life Sciences in the upper half of its industry. The industry median 3-Year ROIIC % is 1.46. RUA Life Sciences' value of 3.13 is 115.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.46, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current 3-Year ROIIC % of 3.13 is 115.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current 3-Year ROIIC % is 3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.24 — trading 86.2% above its estimated fair value. The current 3-Year ROIIC % is 3.13 and 115.1% above the Medical Devices & Instruments industry median of 1.46. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current 3-Year ROIIC % is 3.13 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 86.2% above its estimated GF Value™ of €0.13.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
3-Year ROIIC %: 3.13
GF Value™: €0.13 vs. price of €0.24 (86.2% above fair value)
Industry Position: 115.1% above the Medical Devices & Instruments median (#371 of 794)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
